The site is undergoing maintenance. Ordering can continue through fax and phone.
Sunday, August 16, 2026, 1:30 - 4:30 pm (SAST).
If you encounter problems while ordering. Please contact us at BDBCustomerService@bd.com
See MoreYour selected location is
Middle East / Africa
The site is undergoing maintenance. Ordering can continue through fax and phone.
Sunday, August 16, 2026, 1:30 - 4:30 pm (SAST).
If you encounter problems while ordering. Please contact us at BDBCustomerService@bd.com
See MoreThe site is undergoing maintenance. Ordering can continue through fax and phone.
Sunday, August 16, 2026, 1:30 - 4:30 pm (SAST)
.If you encounter problems while ordering. Please contact us at BDBCustomerService@bd.com
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current location site or be switched to your location?
Two-parameter analysis of the expression of Ly-6G and/or Ly-6C on bone-marrow myeloid cells. C57BL/6 bone marrow cells were stained with either APC-Cy7-conjugated rat IgG2bκ isotype control mAb A95-1 (Cat. No. 552773, left panel) or APC-Cy7 conjugated mAb RB6-8C5 (right panel). Please note that the population of cells having the lowest SSC (erythroid and lymphoid cells) shows little expression of Ly-6G/Ly-6C, while most of the leukocytes with moderate to high SSC (myeloid cells) are Ly-6G/Ly-6c-positive. Flow cytometry was performed on a BD FACSVantage SE™ flow cytometry system.
Two-parameter analysis of the expression of Ly-6G and/or Ly-6C on bone-marrow myeloid cells. C57BL/6 bone marrow cells were stained with either APC-Cy7-conjugated rat IgG2bκ isotype control mAb A95-1 (Cat. No. 552773, left panel) or APC-Cy7 conjugated mAb RB6-8C5 (right panel). Please note that the population of cells having the lowest SSC (erythroid and lymphoid cells) shows little expression of Ly-6G/Ly-6C, while most of the leukocytes with moderate to high SSC (myeloid cells) are Ly-6G/Ly-6c-positive. Flow cytometry was performed on a BD FACSVantage SE™ flow cytometry system.
Two-parameter analysis of the expression of Ly-6G and/or Ly-6C on bone-marrow myeloid cells. C57BL/6 bone marrow cells were stained with either APC-Cy7-conjugated rat IgG2bκ isotype control mAb A95-1 (Cat. No. 552773, left panel) or APC-Cy7 conjugated mAb RB6-8C5 (right panel). Please note that the population of cells having the lowest SSC (erythroid and lymphoid cells) shows little expression of Ly-6G/Ly-6C, while most of the leukocytes with moderate to high SSC (myeloid cells) are Ly-6G/Ly-6c-positive. Flow cytometry was performed on a BD FACSVantage SE™ flow cytometry system.
Two-parameter analysis of the expression of Ly-6G and/or Ly-6C on bone-marrow myeloid cells. C57BL/6 bone marrow cells were stained with either APC-Cy7-conjugated rat IgG2bκ isotype control mAb A95-1 (Cat. No. 552773, left panel) or APC-Cy7 conjugated mAb RB6-8C5 (right panel). Please note that the population of cells having the lowest SSC (erythroid and lymphoid cells) shows little expression of Ly-6G/Ly-6C, while most of the leukocytes with moderate to high SSC (myeloid cells) are Ly-6G/Ly-6c-positive. Flow cytometry was performed on a BD FACSVantage SE™ flow cytometry system.
Two-parameter analysis of the expression of Ly-6G and/or Ly-6C on bone-marrow myeloid cells. C57BL/6 bone marrow cells were stained with either APC-Cy7-conjugated rat IgG2bκ isotype control mAb A95-1 (Cat. No. 552773, left panel) or APC-Cy7 conjugated mAb RB6-8C5 (right panel). Please note that the population of cells having the lowest SSC (erythroid and lymphoid cells) shows little expression of Ly-6G/Ly-6C, while most of the leukocytes with moderate to high SSC (myeloid cells) are Ly-6G/Ly-6c-positive. Flow cytometry was performed on a BD FACSVantage SE™ flow cytometry system.
Two-parameter analysis of the expression of Ly-6G and/or Ly-6C on bone-marrow myeloid cells. C57BL/6 bone marrow cells were stained with either APC-Cy7-conjugated rat IgG2bκ isotype control mAb A95-1 (Cat. No. 552773, left panel) or APC-Cy7 conjugated mAb RB6-8C5 (right panel). Please note that the population of cells having the lowest SSC (erythroid and lymphoid cells) shows little expression of Ly-6G/Ly-6C, while most of the leukocytes with moderate to high SSC (myeloid cells) are Ly-6G/Ly-6c-positive. Flow cytometry was performed on a BD FACSVantage SE™ flow cytometry system.
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
The RB6-8C5 monoclonal antibody recognizes a common epitope on Ly-6G and Ly-6C, previously known as the myeloid differentiation antigen Gr-1. In the bone marrow, the level of antigen expression is directly correlated with granulocyte differentiation and maturation. The antigen is also expressed on the monocyte lineage in the bone marrow, but not on erythroid cells. In the periphery, RB6-8C5 antibody recognizes granulocytes (neutrophils and eosinophils) and monocytes. The RB6-8C5 antibody is a component of the "lineage cocktail" used in studies of hematopoietic cell lineages. The 1A8 antibody (Cat. No. 551461) specifically recognizes Ly-6G, but not Ly-6C.
Based on comparison of the staining patterns given by 1A8 versus RB6-8C5 antibodies on total blood leucocytes, it is evident that the 1A8 antibody stains the RB6-8C5-bright population, corresponding to Ly-6G-expressing granulocytes; whereas, the RB6-8C5-dim population is 1A8-negative and corresponds to Ly-6C-expressing lymphocytes and monocytes. Please refer to the Technical Data Sheets for Cat. No. 551459 and 553128 for more detailed information.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.